Beam is pursuing a long-term, staged development strategy for sickle cell disease that includes three “waves” of ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Sickle cell disease (SCD) is a genetic condition that affects ... This bowl shape is maintained by the healthy, blob-shaped hemoglobin protein. However, in SCD, mutations in hemoglobin change the ...

The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Genetic Carriers for Sickle Cell Disease Have Higher Risks of Blood ... in women who have any combination of a particular gene mutation, estrogen use, or common medical conditions -- specifically ...

In sickle cell disease, a gene mutation causes the hemoglobin molecules ... work in all patients and are not very potent. "The BCL11A protein is the best and most direct target," he says, "but ...

According to National Institutes of Health (NIH) Sickle cell disease is a group of inherited red blood cell disorders that affect haemoglobin, the protein that carries oxygen through the body.

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.